Vergelijking
Eloralintide vs. Liraglutide
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Metabool
Metabool
CAS-nr.
geen gegevens
204656-20-2
Molecuulmassa
geen gegevens
3751 g/mol
Halfwaardetijd
geen gegevens
13 h
Sequentie
geen gegevens
HAEGTFTSDVSSYLEGQAAKEFIAWLVRGRGWerkingsmechanisme
Eloralintide
Eloralintide selectively activates amylin receptors (preferentially AMY1R) and promotes satiety. The approach targets weight loss via the amylin axis, complementary to or independent of GLP-1 agents.
Liraglutide
Liraglutide is a synthetic GLP-1 analog with 97% sequence identity to human GLP-1. A fatty-acid side chain (C16) on Lys-26 reversibly binds serum albumin and protects against DPP-4 degradation. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and modulates central satiety.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane RCT
Studies
2
5
waarvan bij mensen
1
4
Geregistreerde effecten
2
3
Openstaande tegenstrijdigheden
0
1
Gedocumenteerde bijwerkingen
1
1
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between Eloralintide and Liraglutide?
- Eloralintide is classified as "Metabool", while Liraglutide is classified as "Metabool". Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. Liraglutide: GLP-1 receptor agonist with a half-life of about 13 hours. The first daily (not weekly) modern GLP-1 RA — approved as Victoza for type 2 diabetes (2010) and Saxenda for obesity (2014). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Eloralintide or Liraglutide?
- The highest available evidence level is "Humane RCT" for Eloralintide and "Humane RCT" for Liraglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Eloralintide and Liraglutide in Germany and the United States?
- Duitsland: Eloralintide — Niet goedgekeurd, Liraglutide — Op recept. Verenigde Staten: Eloralintide — Niet goedgekeurd, Liraglutide — Op recept. These are factual summaries with source and review date on the individual pages.